HF Advisory Group LLC Sells 1,207 Shares of Cencora, Inc. $COR

Key Points

• HF Advisory Group LLC reduced its stake in Cencora, Inc. by 26.1% during the second quarter, now holding 3,409 shares valued at approximately $1,022,000.
• Cencora reported $4.00 EPS for the last quarter, exceeding estimates, with revenue of $80.66 billion reflecting an 8.7% increase year-over-year.
• The company announced a quarterly dividend of $0.55 per share, resulting in an annual yield of 0.8% with a payout ratio of 22.63%.

HF Advisory Group LLC decreased its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 26.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,409 shares of the company's stock after selling 1,207 shares during the quarter. HF Advisory Group LLC's holdings in Cencora were worth $1,022,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cornerstone Planning Group LLC raised its holdings in Cencora by 106.7% during the 1st quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock valued at $26,000 after acquiring an additional 48 shares during the period. Hoey Investments Inc. bought a new stake in Cencora during the 1st quarter worth approximately $28,000. Costello Asset Management INC bought a new stake in Cencora during the 1st quarter worth approximately $28,000. University of Texas Texas AM Investment Management Co. bought a new stake in Cencora during the 1st quarter worth approximately $39,000. Finally, Vermillion Wealth Management Inc. bought a new stake in Cencora during the 4th quarter worth approximately $38,000. Institutional investors own 97.52% of the company's stock.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 31,350 shares of the company's stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares of the company's stock, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert P. Mauch sold 4,968 shares of the company's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $294.11, for a total transaction of $1,461,138.48. Following the completion of the sale, the chief executive officer directly owned 42,351 shares of the company's stock, valued at $12,455,852.61. This trade represents a 10.50% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 65,475 shares of company stock valued at $19,080,900 in the last ninety days. 10.80% of the stock is owned by corporate insiders.

Cencora Price Performance

COR stock traded down $0.52 during midday trading on Friday, reaching $290.32. The company had a trading volume of 7,182,669 shares, compared to its average volume of 1,405,903. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $309.35. The company has a market capitalization of $56.29 billion, a P/E ratio of 29.87, a P/E/G ratio of 1.38 and a beta of 0.62. The firm has a 50-day moving average price of $292.42 and a 200-day moving average price of $286.81.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, topping analysts' consensus estimates of $3.79 by $0.21. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business had revenue of $80.66 billion during the quarter, compared to analysts' expectations of $80.34 billion. During the same quarter in the previous year, the company earned $3.34 EPS. The business's quarterly revenue was up 8.7% compared to the same quarter last year. On average, research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.8%. Cencora's dividend payout ratio is 22.63%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Jefferies Financial Group upped their target price on shares of Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a report on Monday, June 30th. Wells Fargo & Company upped their target price on shares of Cencora from $337.00 to $354.00 and gave the stock an "overweight" rating in a report on Wednesday, August 13th. Finally, Morgan Stanley set a $330.00 target price on shares of Cencora and gave the stock an "equal weight" rating in a report on Wednesday, July 16th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $311.25.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.